Across 49 European CTIS Phase II–III depression trials, CRO or specialist vendor support was documented in 23 trials, equal to 46.9%. IQVIA was the most active named support organization with 14 trials, followed by Medidata Solutions with 7, and ICON Clinical Research plus Signant Health with 5 each. CRO need increased sharply with trial scale: 17 of 17 trials across 4 or more countries used CRO support, and 17 of 18 trials with 16 or more sites used CRO support.
IQVIA appeared in 14 of 49 trials, or 28.6% of the full cohort, making it the most active support organization in European depression Phase II–III CTIS submissions. Medidata Solutions appeared in 7 trials, while ICON Clinical Research and Signant Health appeared in 5 trials each.
The depression CRO market in CTIS records is led by large global CRO/data vendors rather than only psychiatry-specialist providers. IQVIA’s 14-trial footprint suggests broad Phase III operational involvement, while Medidata and Signant highlight the importance of data capture, eCOA, rating scales, and rater infrastructure in depression trials.
CRO use rose from 3 of 28 single-country trials, or 10.7%, to 17 of 17 trials, or 100.0%, once the study reached 4 or more countries. Site scale showed the same pattern: 17 of 18 trials with 16 or more sites used CRO support, compared with 0 of 16 single-site trials.
The practical CRO trigger is not depression as a disease alone; it is operational complexity. The strongest demand appears when sponsors must coordinate multi-country CTIS submissions, psychiatry site activation, high site counts, patient-facing material localization, vendor governance, and recruitment execution across several EU/EEA markets.
Major depressive disorder accounted for the largest CRO-supported indication base: 20 of 38 MDD trials used CRO support, equal to 52.6%. Bipolar depression had the highest CRO rate among recurring subgroups, with 2 of 3 trials supported by CROs or specialist vendors.
| Indication | CRO-supported | Rate |
|---|---|---|
| Major depressive disorder | 20 / 38 | 52.6% |
| Treatment-resistant depression | 0 / 9 | 0.0% |
| Bipolar depression | 2 / 3 | 66.7% |
| Seasonal affective disorder + MDD | 0 / 2 | 0.0% |
| Postpartum / perinatal depression | 0 / 1 | 0.0% |
CRO demand is concentrated in scalable commercial MDD and bipolar depression programs. Treatment-resistant depression trials in this cohort appear more academic and locally executed, with 0 of 9 trials showing CRO support.
The most common outsourced function was CRO/site operations, appearing in 24 of 49 trials, or 49.0%. Central laboratory or bioanalysis and trial technology/data systems each appeared in 21 trials, while ECG/cardiac safety support appeared in 18 trials.
Depression outsourcing is broader than site monitoring. Sponsors commonly outsource laboratory work, data systems, ECG, electronic clinical outcome assessment, rating-scale/rater training, pharmacovigilance, investigational medicinal product logistics, and patient reimbursement—functions that become especially important in multi-country EU trials.
CRO-supported depression trials were heavily concentrated in multi-country CTIS footprints. Poland had 14 trials and 109 sites with 92.9% CRO support; Bulgaria had 13 trials and 94 sites with 92.3% CRO support; Germany had 13 trials and 82 sites with 92.3% CRO support.
For CTIS and EU submission planning, CRO value appears strongest in coordinating Part II country workflows, local psychiatry sites, country-language patient materials, and vendor packages across high-volume countries. CRO-supported country entries had a median CTIS Part II processing time of 52 days versus 55 days without CRO support, so the business case is stronger for coordination capacity than for authorization-speed advantage alone.
The same CTIS data can answer additional operational questions around sponsor type, digital recruitment, recruitment infrastructure, and Phase III outsourcing intensity.
The highest-value commercial CRO opportunity is not generic depression trial support; it is multi-country Phase III MDD or bipolar depression execution with structured recruitment, CTIS Part II coordination, data/eCOA infrastructure, ECG safety, central laboratory work, and country-specific patient-support logistics.
CRO means contract research organization or a named specialist vendor performing outsourced clinical-trial support. CTIS means Clinical Trials Information System. EU Part II refers to country-level assessment elements such as site, investigator, participant-facing material, informed consent, and local recruitment documentation. eCOA means electronic clinical outcome assessment. IMP means investigational medicinal product.
European depression CRO demand is most predictable once the trial becomes commercial, Phase III, multi-country, and site-dense. For CRO business development, the strongest target profile is a pharma or biotech-sponsored MDD/bipolar depression program with 4 or more countries, 16 or more sites, 250 or more participants, digital or structured recruitment, and multiple CTIS country submissions requiring coordinated local execution.